{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=99", "query": { "intervention": "serum sample", "page": 99 }, "page_size": 10 }, "pagination": { "page": 99, "page_size": 10, "total_count": 8383, "total_pages": 839, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=100&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=98&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T12:24:43.626Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00645593", "title": "Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Gemcitabine,", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2008-03", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-05-23", "last_synced_at": "2026-11-06T12:24:43.626Z", "location_count": 14, "location_summary": "Duarte, California • Los Angeles, California • Stanford, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00645593" }, { "nct_id": "NCT05739981", "title": "Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "IMNN-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Imunon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2023-02-10", "completion_date": "2028-08-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-11-06T12:24:43.626Z", "location_count": 4, "location_summary": "Baltimore, Maryland • New York, New York • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05739981" }, { "nct_id": "NCT04786067", "title": "Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Kidney Transplant Immunosuppression" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-07-28", "completion_date": "2025-07-30", "has_results": true, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-11-06T12:24:43.626Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04786067" }, { "nct_id": "NCT00836407", "title": "Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Pancreatic Cancer Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2009-02", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2020-02-24", "last_synced_at": "2026-11-06T12:24:43.626Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00836407" }, { "nct_id": "NCT03350711", "title": "A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program", "overall_status": "SUSPENDED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Clostridium Difficile Infection" ], "interventions": [ { "name": "Microbiota Enrichment Program (MEP)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2018-09-13", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-11-06T12:24:43.626Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Decatur, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03350711" }, { "nct_id": "NCT02596971", "title": "A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma, Lymphoma Follicular" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2015-12-22", "completion_date": "2020-05-08", "has_results": true, "last_update_posted_date": "2021-05-24", "last_synced_at": "2026-11-06T12:24:43.626Z", "location_count": 9, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 5 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02596971" }, { "nct_id": "NCT05950334", "title": "FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory B-Cell Lymphoma" ], "interventions": [ { "name": "FT522", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-11-16", "completion_date": "2025-06-30", "has_results": false, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-11-06T12:24:43.626Z", "location_count": 7, "location_summary": "Orlando, Florida • Detroit, Michigan • Minneapolis, Minnesota + 4 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05950334" }, { "nct_id": "NCT00804934", "title": "Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Wet AMD" ], "interventions": [ { "name": "Lucentis", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Retina Institute of Hawaii", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 100, "start_date": "2008-02", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2012-05-28", "last_synced_at": "2026-11-06T12:24:43.626Z", "location_count": 1, "location_summary": "Honolulu, Hawaii", "locations": [ { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT00804934" }, { "nct_id": "NCT06366230", "title": "Adding Urea to the Final Dialysis Fluid", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Dysequilibrium Syndrome", "ESRD", "Hyperkalemia", "Metabolic Acidosis" ], "interventions": [ { "name": "Urea in the dialysate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-09-16", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-11-06T12:24:43.626Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06366230" }, { "nct_id": "NCT07715734", "title": "Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplant Recipient", "Cutaneous Squamous Cell Carcinoma (CSCC)", "Advanced Cutaneous Squamous Cell Carcinoma", "Kidney Transplant" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Cetuximab (EGFR inhibitor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2026-11-30", "completion_date": "2031-04-30", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-06T12:24:43.626Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07715734" } ] }